title: Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study.
abstract: BACKGROUND
  To assess baseline characteristics, glycemic control, and treatment with oral antidiabetic drugs (OAD) in type 2 diabetes mellitus (T2DM) patients.
  
  
  METHODS
  This multinational, observational study recruited patients ≥ 21 years of age who were newly diagnosed and/or treated with OAD monotherapy for <6 months but were inadequately controlled. In cross-sectional phase, data on demographics, medical history, diabetic complications and comorbidities, OAD treatment, glycosylated hemoglobin (HbA1c), and fasting blood glucose (FBG) were collected. In longitudinal phase evaluating 6-month follow-up of sulfonylurea (SU)-treated patients, additional data on reasons for not achieving HbA1c targets were collected.
  
  
  RESULTS
  Of 1487 patients (mean [± SD] age 52.0 ± 11.6 years; 46.7% men; mean BMI 25.8 ± 4.4 kg/m(2) ) recruited, 75.9% were newly diagnosed, 73.3% had central obesity, 43.8% had hypertension, and 60.5% had dyslipidemia. The mean HbA1c was 9.8 ± 2.4%, and the mean FBG was 11.3 ± 4.3 mmol/L. At T0 (baseline) and T6 (month 6 visit), 99.8% (n=1066) and 97.1% (n=830) patients received SU, respectively. There was decrease from T0 to T6 in mean HbA1c (10.2% vs 7.3%, respectively; P<0.0001) and mean FBG (12.0 vs 7.6 mmol/L, respectively; P<0.0001). Number of patients with HbA1c <7% increased from T0 (4.5%) to T6 (46.8%). Reasons for not achieving target HbA1c included poor diabetes education (50.7%), non-compliance to OADs (21.4%), and fear of hypoglycemia (19.7%).
  
  
  CONCLUSIONS
  Marked reductions in HbA1c and FBG are achievable in T2DM patients managed with OADs. However, patient education and compliance are important for achieving and maintaining treatment targets.
authors: Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. apichativ2000@yahoo.com
authors: Apichati
authors: A
authors: Vichayanrat
authors: Bien J
authors: BJ
authors: Matawaran
authors: Aris
authors: A
authors: Wibudi
authors: Hossain S
authors: HS
authors: Ferdous
authors: Azizul Hasan
authors: AH
authors: Aamir
authors: Sanjay K
authors: SK
authors: Aggarwal
authors: Shailendra
authors: S
authors: Bajpai
mesh_terms: D000284:Administration, Oral; D000328:Adult; D044466:Asian People / Q000706:statistics & numerical data; D001786:Blood Glucose / Q000378:metabolism*; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000208:ethnology; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000208:ethnology; D005215:Fasting / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000208:ethnology; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications / Q000208:ethnology; D010349:Patient Compliance / Q000706:statistics & numerical data; D010353:Patient Education as Topic / Q000706:statistics & numerical data; D012042:Registries / Q000706:statistics & numerical data; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds
keywords: Asia; oral antidiabetic drugs; sulfonylurea; type 2 diabetes mellitus; 亚洲，口服降糖药，磺脲，2型糖尿病